Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older
- People who have a type of blood cancer called DLBCL (Diffuse Large B-Cell Lymphoma) that has come back or stopped responding to treatment, and who are not suitable candidates for a stem cell transplant
- People for whom a doctor has already independently decided to prescribe the medications tafasitamab and lenalidomide (commercially available versions), and who will begin that treatment after signing the study consent form
- People who are able to read and sign a consent form agreeing to take part in the study
Who may not be able to join:
- People who are currently participating in another clinical trial that involves a medical intervention or treatment
- People whose doctors believe it would be unlikely that reliable medical information could be collected from them at the start of or during the study (confirm with trial site)
- People who have already started treatment with tafasitamab before signing the study consent form
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: + 39 3429513636
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression free survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.